An estimate of pediatric lives saved due to non-pharmacologic interventions during the early COVID-19 pandemic
Faust, J. S.; Renton, B.; Du, C.; Chen, A. J.; Li, S.-X.; Lin, Z.; Krumholz, H. M.
Show abstract
The net effect of the pandemic mitigation strategies on childhood mortality is not known. During the first year of the COVID-19 pandemic, mitigation policies and behaviors were widespread, and although vaccinations and effective treatments were not yet widely available, the risk of death from SARS-CoV-2 infection was low. In that first year, there was a 7% decrease in medical ("natural causes") mortality among children ages 0-9 during the first pandemic year (5% among infants <1 year and 15% among children ages 1-9) in the United States, resulting in an estimated 1,488 deaths due to medical causes averted among children ages 0-9, and 1,938 deaths averted over 24 months. The usual expected surge in winter medical deaths, particularly among children ages >1 year was absent. However, smaller increases in external ("non-natural causes") mortality were also observed during the study period, which decreased the overall number of pediatric deaths averted during both years and the pandemic period. In total, 1,468 fewer all-cause pediatric deaths than expected occurred in the United States during the first 24 months of the COVID-19 pandemic.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program 92%
- Asymptomatic COVID-19 screening tests to facilitate full-time school attendance: model-based analysis of cost and impact 90%
- Pediatric household transmission of SARS-CoV-2 infection 89%
Similar papers in this journal
Similar papers in this journal
- Changes in pneumococcal deaths in the United States following the COVID-19 pandemic 91%
- Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022 91%
- SARS-CoV-2 infections in 171 countries and over time 90%
Similar papers in this journal
- Estimating individual risks of COVID-19-associated hospitalization and death using publicly available data 92%
- Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States 91%
- Reductions in US life expectancy from COVID-19 by Race and Ethnicity: Is 2021 a repetition of 2020? 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.